First human trial launches for experimental cancer therapy
NCT ID NCT07231458
Summary
This is an early-stage study to test the safety and find the right dose of a new drug called ABX-001. It will be given to adults with advanced solid tumors that have stopped responding to standard treatments. The study will test the drug by itself and also in combination with an existing immunotherapy drug, pembrolizumab.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Charite-Universitaetsmedizin Berlin - Campus Benjamin Franklin (CBF)
RECRUITINGBerlin, 12200, Germany
-
Hospital Universitario Fundacion Jimenez Diaz
RECRUITINGMadrid, 28040, Spain
-
The START Center for Cancer Care - CIOCC
RECRUITINGMadrid, 28050, Spain
-
Universitaetsklinikum Tuebingen
RECRUITINGTübingen, 72076, Germany
-
Vall d'Hebron Institut d'Oncologia
RECRUITINGBarcelona, 08035, Spain
Conditions
Explore the condition pages connected to this study.